Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)

PURPOSE: The combination of cyclin-dependent kinase 4/6 inhibitors and endocrine therapy is a standard treatment for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC); however, their toxicities and financial burden are major issues...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Kenichi, Niikura, Naoki, Kikawa, Yuichiro, Oba, Mari, Kobayashi, Kokoro, Tada, Hiroshi, Ozaki, Shinji, Toh, Uhi, Yamamoto, Yutaka, Tsuneizumi, Michiko, Okuno, Toshitaka, Iwakuma, Nobutaka, Takeshita, Takashi, Iwamoto, Takayuki, Ishiguro, Hiroshi, Masuda, Norikazu, Saji, Shigehira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175424/
https://www.ncbi.nlm.nih.gov/pubmed/37000345
http://dx.doi.org/10.1007/s10549-023-06911-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175424/
https://www.ncbi.nlm.nih.gov/pubmed/37000345
http://dx.doi.org/10.1007/s10549-023-06911-5

Ejemplares similares